A Moving Target: Impacts of Lowering Viral Load Suppression Cutpoints on Progress Towards HIV Epidemic Control Goals

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was supported by the National Institute of Allergy and Infectious Diseases (NIAID) (U01AI100031, U01AI075115, R01AI110324, R01AI128779, R01AI123002, R01AI143333, R01AI55080, T32AI102623); the National Institute of Mental Health (R01MH105313); the Division of Intramural Research of the NIAID; and the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (CDC) under the terms of NU2GGH000817. JGR and KBR were supported by the National Institute of Mental Health (F31MH126796, K01MH129226). The content is solely the responsibility of the authors and does not necessarily reflect the official views of the funding agencies.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by the Uganda Virus Research Institute Research and Ethics Committee and the Johns Hopkins University School of Medicine Institutional Review Board. This project was reviewed in accordance with CDC human research protection procedures and was determined to be research, but CDC investigators did not interact with human subjects or have access to identifiable data or specimens for research purposes.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes